Additional Information
Market: AIM
Sector: Software & Computer Services
EPIC: CRW
Latest Price: 527.50p  (0,00%)
52-week High: 622.50p
52-week Low: 354.63p
Market Cap: 140.39M
1 year chart More charts
Deal CRW Tax Free*
*subject to change and depends on individual circumstances.
1 day chart More charts
Advertisement
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Craneware plc
www.craneware.com
Deal Craneware plc Tax Free* Losses can exceed
your initial deposit
*subject to change and depends on individual circumstances.
Craneware provides proprietary revenue cycle management software solutions for the US healthcare provider market.
Pdf

Craneware's top line growth on track

January 21 2013, 8:24am Underlying earnings (EBITDA) grew by around 15% in comparison to last year’s interim EBITDA of US$4.65mln.

 

Craneware (LON:CRW), the software solutions provider focused on the US healthcare market, saw first half revenue grow in line with expectations.

Revenue of US$20.1mln in the first half of the current financial year was up from US$18.8mln in the first half of last year.

Underlying earnings (EBITDA) grew by around 15% in comparison to last year’s interim EBITDA of US$4.65mln.

Keith Neilson, chief executive of Craneware, commented: "The increased levels of sales activity discussed at the time of our final results in September 2012 have begun to contribute to revenue growth. Fiscal and regulatory pressures on US hospitals, including the recently announced expansion of the Medicare Recovery Audit Contractor Programme, continues to drive interest in our suite of software solutions and we are confident in the ongoing strength of our position within this growing area of the US healthcare market."

Shares in Craneware were unchanged in early trading.

 

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.